LYMPHOMAS

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase inhibitors and degraders.

Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in Waldenström macroglobulinemia.

David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.

Fixed-duration glofitamab combined with polatuzumab vedotin achieved high response rates and sustained remissions in heavily pretreated relapsed/refractory large B-cell lymphoma.

Elizabeth A. Brem, MD, discusses treatment options for patients with diffuse large B-cell lymphoma.

Elizabeth A. Brem, MD, discusses the familiarity of treatments among oncologists for patients with diffuse large B-cell lymphoma in a Case-Based Roundtable event.

Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.

Elizabeth A. Brem, MD, discusses the shift she has seen in the community setting when it comes to using bispecific antibody therapy for patients with B-cell lymphoma.

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether participants with use this treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.

The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.

Golcadomide plus R-CHOP was well tolerated and demonstrated high metabolic response rates that were durable in patients with previously untreated a-BCL.

Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult patients with cutaneous T-cell lymphoma.

Valemetostat showed promise as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma.

While challenges exist in treating peripheral T-cell lymphoma, ongoing research is developing more effective therapies.

Reid W. Merryman, MD, discussed the latest developments with minimal residual disease assays in the management of patients with lymphoma.

The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.

Following voluntary withdrawal in 2014, denileukin diftitox is now available again for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

The combination of englumafusp alfa and glofitamab showed a BOR of 67.0% and CR rate of 57.0% in second-line settings. In third-line settings, the BOR was 65.7% and the CR rate was 52.8%.

ATO/ATRA plus idarubicin showed superior 2-year EFS (88% vs 70%) and 5-year EFS (87% vs 55%) compared to ATRA/chemotherapy. The trial indicated lower hematologic toxicity with ATO/ATRA, including reduced rates of thrombocytopenia and neutropenia.

During a Case-Based Roundtable® event, Joanna M. Rhodes, MD, MSCE, discussed issues related to toxicity and dose modification in treating patients with Hodgkin lymphoma.

During a Case-Based Roundtable® event, Matthew Ulrickson, MD, considered treatments for patients with relapsed/refractory diffuse large B-cell lymphoma with event participants in the second article of a 2-part series.

Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.